Obesity News

Childhood cancer survivors in France are less likely to develop obesity compared with the country’s general population, according to a study published in Obesity.

Adults with diabetes who smoke or exercise less than once per week are among those at higher risk for a lower limb amputation, but adults with obesity may have a lower risk for amputations, according to study data.

Although telephone-based cognitive behavioral therapy did not change short-term weight outcomes in patients 1 year after bariatric surgery, it did improve disordered eating and psychological distress, researchers reported.

When taken over 2 years for rheumatoid arthritis, low-dose glucocorticoids were associated with slight weight gain, but they did not significantly affect BP, according to research published in Annals of Internal Medicine.

Adults with overweight or obesity and metabolic dysfunction-associated steatotic liver disease had a more than 5% reduction in liver fat at 6 months with growth hormone therapy, according to findings from a randomized controlled trial.

Adults with overweight or obesity in the U.S. have a one in 10 annual probability of achieving a 5% or greater weight loss, and the likelihood for weight loss increases with a higher initial BMI, according to study data.

In response to safety concerns surrounding sedation for patients prescribed glucagon-like peptide-1 receptor agonists, the AGA, AASLD, ACG, ASGE and NASPGHAN encourage gastroenterologists to follow “best practices” for endoscopy procedures.

Compared with placebo, injectable semaglutide 2.4 mg reduced risk for major adverse CV events by 20% for people with overweight or obesity and established CVD, according to topline data from the SELECT study.

The AGA applauded the reintroduction of the Treat and Reduce Obesity Act into the 118th Congress as this bill would expand Medicare coverage for screening and treatment of obesity by health care providers specializing in obesity care.

A personal injury law firm has filed a lawsuit against Novo Nordisk and Eli Lilly, alleging the manufacturers “downplayed the severity of the gastrointestinal events caused by Ozempic and Mounjaro,” such as gastroparesis and gastroenteritis.